March 31, 2022 Price forecast | 2 weeks: 4.44% | 1 month: 4.68% | 3 months: 3.21%


CRVS stock forecast

Our latest prediction for Corvus Pharmaceuticals Inc's stock price was made on the March 31, 2022 when the stock price was at 1.64$.

In the short term (2weeks), CRVS's stock price should outperform the market by 4.44%. During that period the price should oscillate between -10.36% and +19.01%.

In the medium term (3months), CRVS's stock price should outperform the market by 3.21%. During that period the price should oscillate between -38.72% and +51.84%.

Create a solid portfolio with CRVS

Add CRVS to your portfolio and optimize it!


About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.03$ per share.

The book value per share is 4.36$

Corvus Pharmaceuticals Inc website


Three months stock forecastMarch 31, 2022


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -39M - -43M -1.03 - - 42M 4.36 -37M - -37M